EGFR down-regulation was also observed in other NSCLC cells, including PDCs, as well as in HCA46 CRC cells (Fig. 4B and Supplementary Fig. 5A), while the other multikinase inhibitors sunitinib and regorafenib did not inhibit the receptor or had much weaker effects compared to sorafenib (Supplementary Fig. 5B). This evidence concerns the gene EGFR and non-small cell lung carcinoma.